Last reviewed · How we verify
NCT06973902: PREDICT-CCM
The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF
trial testing Cardiac Contractility Modulation (CCM) implant in Symptomatic Congestive Heart Failure in 120 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Quovadis Associazione |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 10 July 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 13 locations across Italy |
Drugs / interventions tested
- Cardiac Contractility Modulation (CCM) implant
Conditions studied
- Symptomatic Congestive Heart Failure — all drugs for Symptomatic Congestive Heart Failure →
Sponsor
Quovadis Associazione — full company profile →
Who can join
18 and older, any sex, with Symptomatic Congestive Heart Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational cohort study, which is both retrospective and prospective, is to evaluate the long-term clinical and instrumental response to Cardiac Contractility Modulation (CCM) treatment in adult subjects suffering from symptomatic heart failure (HF) due to systolic left ventricular dysfunction, despite adequate medical therapy. Based on the response to stress echocardiography with preimplantation low-dose Dobutamine, the main questions it aims to answer are: * What is the proportion of subjects who experience a clinical response to CCM therapy at 12 months (NYHA reduction ≥ 1 class)? * There was a reduction in the number of hospitalizations, visits to the Emergency Department, and access to day hospital facilities for more than 4 hours compared to the year before the study (e.g., by intravenous infusion of cardiac inotropic drugs)? * What is the estimated change in the quality-of-life score using the "Quality of Life Questionnaire with Heart Failure - Minnesota" (MLHFQ) between baseline and the end of follow-up? * What is the change in walking distance between baseline and the end of the follow-up in the walk test (6MWT) (optional)? * What is the difference in NT-proBNP levels between baseline and the end of follow-up? Participants are already receiving CCM support as part of their regular medical care for heart failure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06973902
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Quovadis Associazione trials
Trials by the same sponsor.
- NCT04393805 — Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto · completed
- NCT04359212 — Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19 · completed
- NCT04329390 — MAC Project, Monitoring of AntiCoagulant Therapies (MAC) · completed
- NCT03428711 — Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06973902 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Quovadis Associazione
- Last refreshed: 29 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06973902.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing